(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 May 2019 (23.05.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/099735 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61K 47/32* (2006.01)
A61K 47/26 (2006.01)

(21) International Application Number:
PCT/US2018/061375

(22) International Filing Date:
15 November 2018 (15.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/586,643 15 November 2017 (15.11.2017) US

(71) Applicant: **RHYTHM PHARMACEUTICALS, INC.** [US/US]; 500 Boylston St., 11th Floor, Boston, MA 02116 (US).

(72) Inventors: **DEY, Michael, John**; 40 Park Lane, Sanbach, Cheshire CW11 1EW (GB). **GAUTAM, Jaya**; 500 Boylston St., 11th Floor, Boston, MA 02116 (US). **HENDERSON, Barton, T.**; 500 Boylston St., 11th Floor, Boston, MA 02116 (US). **JOHNSSON, Markus**; Camurus AB, Sölvegatan 41, SE-22370 Lund (SE). **LINDMAN, Stina**; Camurus AB, Sölvegatan 41, SE-22370 Lund (SE).

(74) Agent: **COLLAZO, Diana, M.** et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2019/099735 A1

(54) Title: SUSTAINED RELEASE PEPTIDE FORMULATIONS

(57) Abstract: This disclosure provides, at least in part, a pharmaceutical product comprising: setmelanotide (also known as RM493); setmelanotide as sole active pharmaceutical ingredient formulated for injection; setmelanotide as the sole active ingredient; setmelanotide as the active pharmaceutical ingredient; setmelanotide as the active pharmaceutical ingredient for injection; or another pharmaceutical composition that has its primary mechanism of action at the MC4 receptor as an agonist (referred to herein as an MC4RAp), e.g., a lipid excipient, and/or a pharmaceutically acceptable carrier. The pharmaceutical product described herein provides a sustained release of setmelanotide or another pharmaceutical composition, which may result in a more desirable pharmacokinetic and pharmacodynamic profile upon administration.